Broadening global access to epilepsy treatment

At UCB, we believe that all patients who need our treatments should have access to them now and in the future.

We have a rich heritage in epilepsy, with over 30 years of experience in the research, development, and delivery of antiseizure medications, and we are committed to broadening access to these solutions for people living in low- and middle-income countries, where epilepsy is still an important cause of disability and mortality.

Aligned with that commitment, I am pleased to report that UCB recently received news from the Rwandan Food and Drugs Authority that levetiracetam has been registered and approved for use in the country - indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy; indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy, in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy, in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy . This marks an important milestone being the first time that UCB has successfully registered the treatment in a sub-Saharan country.

This approval comes swiftly on the heels of the inclusion of levetiracetam in the World Health Organization Model List of Essential Medicines (WHO EML) in July 2023 .

We look forward to providing more updates in the future.